MGMT promoter methylation in IDH mutant gliomas is a result of metabolic alterations including increased production of 2-D-HG and genome-wide methylation (Turcan et al., 2012; Lu et al., 2012; Figueroa et al., 2010). This evidence concerns the gene IDH2 and central nervous system cancer.